Search
Aclaris Therapeutics Inc
ACRSAdd to Watchlist
5.250USD
+0.050+0.96%
Close 07-31 16:00（ET）Quotes delayed by 15 min
733.18MMarket Cap
LossP/E TTM
More Details of Aclaris Therapeutics Inc Company
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
Aclaris Therapeutics Inc Info
Ticker SymbolACRS
Company nameAclaris Therapeutics Inc
IPO dateOct 07, 2015
CEOWalker (Neal S)
Number of employees64
Security typeOrdinary Share
Fiscal year-endOct 07
Address701 Lee Road
CityWAYNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19087
Phone14843247933
Websitehttps://www.aclaristx.com/
Ticker SymbolACRS
IPO dateOct 07, 2015
CEOWalker (Neal S)
Company Executives of Aclaris Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James (Jim) Loerop
Mr. James (Jim) Loerop
Chief Business Officer
Chief Business Officer
192.26K
--
Mr. Christopher P. Molineaux
Mr. Christopher P. Molineaux
Lead Independent Director
Lead Independent Director
69.54K
+16.65%
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
45.10K
+25.67%
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Director
Independent Director
33.33K
+34.74%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
28.90K
+40.07%
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Independent Director
Independent Director
25.54K
+45.34%
Dr. Neal S. Walker
Dr. Neal S. Walker
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Independent Director
Independent Director
--
--
Mr. Kevin Balthaser
Mr. Kevin Balthaser
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Hugh M. Davis, Ph.D.
Dr. Hugh M. Davis, Ph.D.
President, Chief Operating Officer, Director
President, Chief Operating Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James (Jim) Loerop
Mr. James (Jim) Loerop
Chief Business Officer
Chief Business Officer
192.26K
--
Mr. Christopher P. Molineaux
Mr. Christopher P. Molineaux
Lead Independent Director
Lead Independent Director
69.54K
+16.65%
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
45.10K
+25.67%
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Director
Independent Director
33.33K
+34.74%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
28.90K
+40.07%
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Independent Director
Independent Director
25.54K
+45.34%
FAQs
Who are the top five shareholders of Aclaris Therapeutics Inc?
The top five shareholders of Aclaris Therapeutics Inc are: Mr. James (Jim) Loerop
How many institutions hold shares of Aclaris Therapeutics Inc (ACRS)?
As of 2026Q1, 267 institutions hold shares of Aclaris Therapeutics Inc, with a combined market value of approximately 101.56M, accounting for 72.75% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 10925.00.
What is the biggest source of revenue for Aclaris Therapeutics Inc?
In 2026Q1, the Licensing business generated the highest revenue for Aclaris Therapeutics Inc, amounting to 5.95M and accounting for 76.08% of total revenue.